公开(公告)号：EP3087101A4

公开(公告)日：2017-12-06

申请号：EP14872734

申请日：2014-12-19

申请人： NOVARTIS AG ,  UNIV PENNSYLVANIA ,  BROGDON JENNIFER ,  ENGELS BORIS ,  GLASS DAVID JONATHAN ,  GRANDA BRIAN ,  HASTEWELL JOHN ,  LOEW ANDREAS ,  MANNICK JOAN ,  MILONE MICHAEL C ,  MURPHY LEON ,  SELLERS WILLIAM RAJ ,  SONG HUIJUAN ,  VASH BRIAN EDWARD ,  WEILER JAN ,  WU QILONG ,  ZHOU LI

发明人： BROGDON JENNIFER ,  ENGELS BORIS ,  GLASS DAVID JONATHAN ,  GRANDA BRIAN ,  HASTEWELL JOHN ,  LOEW ANDREAS ,  MANNICK JOAN ,  MILONE MICHAEL ,  MURPHY LEON ,  SELLERS WILLIAM RAJ ,  SONG HUIJUAN ,  VASH BRIAN EDWARD ,  WEILER JAN ,  WU QILONG ,  ZHOU LI

IPC分类号： C07K19/00 ,  A61K31/436 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC分类号： C07K16/2863 ,  A61K31/436 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/71 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/41 ,  C07K2319/43 ,  C07K2319/70 ,  C12N9/1205 ,  C12N9/90 ,  C12Y502/00

摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

公开(公告)号：EP3119425A4

公开(公告)日：2017-11-22

申请号：EP15764851

申请日：2015-03-13

申请人： NOVARTIS AG ,  UNIV PENNSYLVANIA ,  ENGELS BORIS

发明人： ENGELS BORIS ,  LOEW ANDREAS ,  MILONE MICHAEL C ,  ZHOU LI

IPC分类号： A61K39/00 ,  A61K38/00

CPC分类号： C07K16/2863 ,  A61K38/00 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/0011 ,  A61K39/3955 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/55561 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70575 ,  C07K16/00 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/22 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/10 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/70 ,  C07K2319/73 ,  C12N15/62

摘要： Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.